Common use of Consideration and Payments Clause in Contracts

Consideration and Payments. a) Contingent on the Sponsor’s compliance with the obligations set forth herein, BIOENVISION shall provide the Sponsor with an initial Clinical Trial set up payment of [****] and further payments based on the provision of summary status reports as set out in paragraph 2(f) and as detailed in Appendix B. The final payment will be due on delivery of the final Clinical Trial Report and publishable manuscript provided for in Section 2(g), in each case, as more fully described in the Financial Support Schedule attached hereto as Appendix B. b) BIOENVISION’S payment obligations set forth in Section 3(a) and Appendix B attached hereto are contingent upon Sponsor’s obligation to reimburse BIOENVISION for the cost associated with the supply of clofarabine, as detailed in the Financial Support Schedule attached hereto as Appendix B. c) All payments by BIOENVISION under this Section 3 shall be made within thirty (30) days of the end of the month in which the Sponsor’s invoice (notification of meeting the respective milestone as set in the Financial Support Schedule (Appendix B)) is received. Each invoice shall set forth in reasonable detail the status of the Clinical Trial or relevant Clinical Trial report, as applicable, and the description and amount due. Matters in dispute shall be payable upon mutual resolution of such disputes. The Sponsor shall be prepared to follow up with any and all such supporting documentation reasonably requested by BIOENVISION. All payments by Sponsor to BIOENVISION shall be made within sixty (60) days of the end of the month in which BIOENVISION’S Invoice is delivered. BIOENVISION’s payment will be made to: AML 16 Bioenvision Account RACD Finance Department Cardiff University

Consideration and Payments. a) Contingent on the Sponsor’s compliance with the obligations set forth herein, BIOENVISION shall provide the Sponsor with an initial Clinical Trial set up payment of [****] and further payments based on the provision of summary status reports as set out in paragraph 2(f) and as detailed in Appendix B. The final payment will be due on delivery of the final Clinical Trial Report and publishable manuscript provided for in Section clause 2(g), in each case, as more fully described in the Financial Support Schedule attached hereto as Appendix B. b) BIOENVISION’S payment obligations set forth in Section clause 3(a) and Appendix B attached hereto are contingent upon Sponsor’s obligation to reimburse BIOENVISION for the cost associated with the supply of clofarabine, as detailed in the Financial Support Schedule attached hereto as Appendix B. c) All payments by BIOENVISION under this Section clause 3 shall be made within thirty (30) days of the end of the month in which the Sponsor’s invoice (notification of meeting the respective milestone as set in the Financial Support Schedule (Appendix B)) is received. Each invoice shall set forth in reasonable detail the status of the Clinical Trial or relevant Clinical Trial report, as applicable, and the description and amount due. Matters in dispute shall be payable upon mutual resolution of such disputes. The Sponsor shall be prepared to follow up with any and all such supporting documentation reasonably requested by BIOENVISION. All payments by Sponsor to BIOENVISION shall be made within sixty (60) days of the end of the month in which BIOENVISION’S Invoice is delivered. BIOENVISION’s payment will be made to: AML 16 Bioenvision Account RACD Finance Department Cardiff University